Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Eleonora Gusmaroli
Observed names:
E Gusmaroli,
E. Gusmaroli
Institution:
Fondazione IRCCS Istituto Nazionale dei Tumori
Observed institutions:
Humanitas University,
Fondazione IRCCS Istituto Nazionale dei Tumori,
IRCCS Humanitas Research Hospital
ORCID:
0009-0006-1462-019X
Observed ORCID:
0009-0006-1462-019X
OpenAlex ID:
A5001585357
NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis
2024
·
Federico Nichetti
, Simone Rota
, et al.
·
JAMA Network Open
·
164
PDF
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data
2023
·
Margherita Rimini
, Lorenzo Fornaro
, et al.
·
Liver International
·
125
PDF
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study
2024
·
Margherita Rimini
, Gianluca Masi
, et al.
·
Targeted Oncology
·
34
PDF
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab
2024
·
Margherita Rimini
, Eleonora Loi
, et al.
·
Targeted Oncology
·
12
PDF
NALIRIFOX vs FOLFIRINOX vs gemcitabine plus nab-paclitaxel as first-line treatment of advanced pancreatic cancer: An individual patient data pooled analysis of phase 3 registration trials.
2023
·
Federico Nichetti
, Simone Rota
, et al.
·
Journal of Clinical Oncology
·
7
PDF
Long-term disease stability with bicalutamide in a man with aggressive angiomyxoma: case report and state of art
2024
·
Andrea Franza
, Eleonora Gusmaroli
, et al.
·
Frontiers in Oncology
·
5
PDF
Clinical usability of an explainable AI decision support tool and evaluation of multimodal models in NSCLC
2026
·
Arsela Prelaj
, Vanja Miskovic
, et al.
·
Nature Medicine
·
4
FOLFOX Versus FOLFIRI as Second‐Line Chemotherapy in Patients With Advanced Biliary Tract Cancers: A Multicenter, Italian Study
2025
·
Chiara Pircher
, Federico Nichetti
, et al.
·
Liver International
·
4
PDF
Hot topics in genitourinary cancers: A multidisciplinary discussion on state-of-the-art and latest developments among international experts and patient advocacy
2024
·
Alessandro Rametta
, Paolo Ambrosini
, et al.
·
Tumori Journal
·
4
Design and rationale of the phase II PANDORA trial: first line chemo-immunotherapy in advanced Merkel cell carcinoma
2025
·
Simone Oldani
, Natalie Prinzi
, et al.
·
Future Oncology
·
3
Nectin-4 and Trop-2 expression as potential therapeutic target in collecting duct carcinoma: Preliminary results from the CICERONE trial (NCT05372302).
2025
·
Giuseppe Procopio
, Alessandro Rametta
, et al.
·
Journal of Clinical Oncology
·
2
A Comparative Study of Methyl-BEAMing and Droplet Digital PCR for MGMT Gene Promoter Hypermethylation Detection
2024
·
Marco Macagno
, Valeria Pessei
, et al.
·
Diagnostics
·
2
PDF
Evaluation of clinical benefit and progression-free survival ratio of targeted treatments in a prospective cohort study of patients with biliary tract cancers.
2023
·
Monica Niger
, Federico Nichetti
, et al.
·
Journal of Clinical Oncology
·
2
Lynch syndrome–associated urothelial carcinoma: clinical and molecular findings from a single-institution cohort
2026
·
A. Rametta
, M. Barella
, et al.
·
Familial Cancer
·
1
PDF
Nectin-4 and Trop-2 expression in collecting duct carcinoma: new promising therapeutic targets
2026
·
A. Rametta
, M. Stellato
, et al.
·
ESMO Open
·
1
PDF
P1.11.01 First-Line Nivolumab Plus Ipilimumab in Combination With Chemotherapy for Metastatic NSCLC: Real World Data in Italy
2025
·
F. Agustoni
, G. Gambini
, et al.
·
Journal of Thoracic Oncology
·
1
Targeting Cyclin-Dependent Kinase 4 Amplifications: A Pioneering Case of Metastatic Leydig Cell Tumor Responding to Abemaciclib
2025
·
Amedeo Nuzzo
, Marco Barella
, et al.
·
JCO Precision Oncology
·
1
Association of myeloid-derived suppressor cell (MDSC) dynamics with clinical response to nivolumab in metastatic clear cell renal carcinoma patients (mRCC): Results from the I-RENE Meet-URO 8 study.
2025
·
Elena Verzoni
, Monica Rodolfo
, et al.
·
Journal of Clinical Oncology
·
1
P-169 Early-onset biliary tract cancer: An overview of clinical presentation, risk factors, molecular profile and outcome in a multicentric Italian cohort
2023
·
C. Vivaldi
, V. Genovesi
, et al.
·
Annals of Oncology
·
1
PDF
Supplementary Figure S1 from Prognostic Modeling Integrating RAS and SMAD4 Status in Patients with BRAF Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer
2026
·
Vincenzo Nasca
, Gabriele Tinè
, et al.
Figure 2 from Prognostic Modeling Integrating RAS and SMAD4 Status in Patients with BRAF Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer
2026
·
Vincenzo Nasca
, Gabriele Tinè
, et al.
Supplementary Table S3 from Prognostic Modeling Integrating RAS and SMAD4 Status in Patients with BRAF Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer
2026
·
Vincenzo Nasca
, Gabriele Tinè
, et al.
Figure 3 from Prognostic Modeling Integrating RAS and SMAD4 Status in Patients with BRAF Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer
2026
·
Vincenzo Nasca
, Gabriele Tinè
, et al.
Supplementary Figure S9 from Prognostic Modeling Integrating RAS and SMAD4 Status in Patients with BRAF Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer
2026
·
Vincenzo Nasca
, Gabriele Tinè
, et al.
Supplementary Figure S5 from Prognostic Modeling Integrating RAS and SMAD4 Status in Patients with BRAF Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer
2026
·
Vincenzo Nasca
, Gabriele Tinè
, et al.
Show more works
View as search
Works count:
59
Citation count:
374
H-index:
5
I10-index:
4
Year
Topic
Type